Mangalam drugs & organics Limited has disclosed its latest bank loan default figures, with total overdue amounts remaining unchanged at ₹1,585.29 lakh across two major banking institutions. The pharmaceutical company made this subsequent disclosure on March 17, 2026, under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, showing no change from its previous February notification.

Current Default Status and March Update

The company's loan defaults continue to involve cash credit facilities with two prominent banks, with the latest disclosure showing identical overdue amounts as of March 15, 2026:

The figures remain identical to those reported in February 2026, indicating no progress in reducing the outstanding obligations despite continued efforts by the management. The defaults have now persisted for approximately five months since their inception in October 2025.

Regulatory Compliance and Disclosure Timeline

The March 17, 2026 disclosure was made in compliance with SEBI regulations that require listed entities to report defaults on loan obligations when outstanding balances remain continuously in excess of sanctioned limits or drawing power for more than 30 days. The company filed its subsequent disclosure with both BSE Limited and National Stock Exchange of India Limited, providing updated details of the defaulted accounts.

This represents the latest in a series of monthly disclosures, following previous notifications in February 2026 and January 2026, demonstrating the persistent nature of the financial challenges and the company's commitment to regulatory transparency.

Management Response and Ongoing Efforts

Mangalam Drugs and Organics Limited has acknowledged the continued defaults and reiterated its commitment to addressing the situation. The company stated it is making arrangements to pay the overdue amounts as soon as possible, maintaining its position on resolving the financial obligations despite no apparent progress in the past month.

The disclosure was signed by Managing Director Govardhan M. Dhoot, with Chief Financial Officer Jeevan Dalvi also involved in the internal communication process. The company has assured stakeholders that efforts remain underway to clear the outstanding dues with both banking institutions, though the unchanged figures suggest ongoing challenges in debt resolution.

Mangalam Drugs & Organics Limited has announced the release of pledged shares by its promoter, marking a significant development in the company's shareholding structure. The pharmaceutical company disclosed this transaction in compliance with SEBI regulations governing substantial acquisition of shares and takeovers.

Release of Pledged Shares

Promoter Aditya Ramniwas Dhoot released 89,000 pledged shares on March 16, 2026, representing 0.56% of the company's total share capital. The shares were previously pledged to M/s Famy care Private Ltd as security for debt obligations.

Current Shareholding Position

Following the release of pledged shares, Dhoot's overall holding in Mangalam Drugs & Organics Limited remains unchanged. His current shareholding details reflect his continued commitment to the company.

Regulatory Compliance

The disclosure was made on March 18, 2026, pursuant to Regulations 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company submitted the required documentation to both BSE Limited and National Stock Exchange of India Limited, where its shares are listed.

The transaction represents a routine corporate action involving the release of share pledges, which were originally created as security arrangements. Such disclosures ensure transparency in promoter shareholding patterns and compliance with regulatory requirements for listed companies in the pharmaceutical sector.